Loading…
Employees: 61
Size Zevra Therapeutics (ZVRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $690M, the 2494th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.59 on 6 Nov 2026.
Performance Over six months the shares gained 4.1%, against -5.6% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 75.1% over the last twelve months (peer median +11.8%); the operating margin is 31.5% (peer median 11.5%).
Valuation It trades at 11.8× forward earnings against a peer median of 16.4× (3rd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +52%, so the hurdle is -52 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 72.5 points above its cost of capital (9.9% WACC).
Short interest Short interest is 10.5% of the free float (15 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $148M | $106M | $23.6M | $27.5M | $10.2M |
| Revenue growth | — | +351% | -14% | +170% | — |
| Gross profit | $140M | $85.9M | $3.57M | $23.5M | $8.99M |
| EBITDA | $47.9M | -$179,000 | -$80.6M | -$48.6M | -$24.0M |
| Net income | $75.0M | $77.6M | -$106M | -$46.0M | -$26.8M |
| Free cash flow | $38.3M | -$2.43M | -$69.7M | -$33.8M | -$18.8M |
| Capital expenditure | $459,000 | $835,000 | $0 | $296,000 | $93,000 |
| Total debt | $1.23M | $63.2M | $60.3M | $43.8M | $14.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZVRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.4% | -4.0% | 4th highest of 21 |
| 6-month return | +4.1% | -5.6% | 8th highest of 21 |
| Distance from 52-week high | -22.9% | -26.1% | 10th highest of 21 |
| Revenue growth (TTM) | +75.1% | +11.8% | 3rd highest of 17 |
| Operating margin | 31.5% | 11.5% | 4th highest of 16 |
| Forward P/E | 11.8× | 16.4× | 3rd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 0.0% | 10.5% | 4th least demanding of 10 |
| Growth delivered (Del g) | +51.6% | +7.9% | highest of 10 |
| Hurdle (Req g minus delivered) | -51.7 pp | +15.6 pp | least demanding of 10 |
| ROIC minus cost of capital | +72.5 pp | -3.1 pp | highest of 14 |
| EV / EBITDA | 10.3× | 8.2× | 4th most expensive of 8 |
| Net debt / EBITDA | -4.1× | -1.0× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | n/a | n/a | n/a |